Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
India and emerging markets emerging as biosimilar GLP-1 production hubs: India's pharmaceutical manufacturing capability established through insulin biosimilars is being retargeted toward semaglutide biosimilar production ahead of the 2032 US patent expiry
We provide flexible customization services including: 99% pure GHK-Cu powder 0.1% / 0.5% / 1% / 5% liquid solutions Water, glycerin or butylene glycol solvent systems Preservative system customization GHK-Cu blended ingredients (such as HA, Centella asiatica, Ectoin) Private label and customized packaging Our technical team can assist with formulation recommendations and stability evaluation
BPC-157 must be prescribed and supervised by a licensed medical provider after a clinical evaluation
Qualified buyers can see why the listing may earn a closer look, while also seeing the checks that still belong in their own buying process
Individuals interested in learning more about physician-guided treatment options can explore our BPC-157 Therapy Program or visit our Peptide Therapy Clinic
US$ 20.10
US$ 23.76
US$ 21.72
